Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest Biological warfare Stories

2014-04-15 12:30:30

BOSTON, April 15, 2014 /PRNewswire-USNewswire/ -- Boston City Council Committee on Government Operations, chaired by Councilors Michael Flaherty & Tito Jackson, to conduct April 16 hearing on Docket #0227, An Ordinance Regarding the Prohibition of Research Designated as Biosafety Level 4, Sponsored by Councilors Charles Yancey, Tito Jackson & Ayanna Pressley. http://photos.prnewswire.com/prnvar/20140415/73231 Community residents, scientific experts and civic advocates to...

2014-04-07 08:32:23

ANNAPOLIS, Md., April 7, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced today that it has received notice from the Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA), advising the Company of its decision to de-scope the current SparVax(®) anthrax vaccine contract through a partial termination for convenience. BARDA will provide additional guidance to PharmAthene on the contractual changes, following which...

2014-04-01 16:25:27

ANNAPOLIS, Md., April 1, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced today that data from the Company's SparVax(® )next-generation anthrax vaccine program were recently presented at the 8(th) Annual New Technologies, New Vaccines conference. In a presentation entitled, "Factors that Affect Potency and Stability for a Recombinant Protective Antigen Vaccine," Dr. Bradford Powell, Director, Analytical Sciences at PharmAthene, presented results demonstrating the Company's...

2014-03-26 08:28:41

PRINCETON, N.J., March 26, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today its financial results for the year ended December 31, 2013. Soligenix's revenues for the year ended were $3.2 million as compared to $3.1 million for...

2014-03-20 23:03:41

BioFire Defense of Salt Lake City, Utah announced today that it was awarded the Next Generation Diagnostic System (NGDS) Technology Development contract by the US Department of Defense. Salt Lake City, UT (PRWEB) March 20, 2014 BioFire Defense, LLC of Salt Lake City, UT announced today that it was awarded the Next Generation Diagnostic System (NGDS) Technology Development contract by the US Department of Defense (DoD) after 12 months of competitive prototyping. The 8 year $240M biodefense...

2014-03-10 12:25:52

PINE BROOK, N.J., March 10, 2014 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 13/076,082, granting a patent which covers methods of preventing or treating anthrax with ETI-204, the company's anti-anthrax antibody, together with antibiotics. The patent also...

2014-03-05 08:20:33

Hawaii Biotech Receives DoD Contract to Develop Anti-Botulism Drug HONOLULU, March 5, 2014 /PRNewswire/ -- The Department of Defense, Defense Threat Reduction Agency, has awarded Hawaii Biotech, Inc., a contract to continue developing drugs to block botulinum toxin, the toxin that causes the life-threatening disease, botulism. There is no therapeutic drug currently available for the treatment of botulism. The award has a first-year period of performance through early 2014, followed...

2014-02-14 08:25:55

Soligenix Initiates Medical Countermeasure Development of SGX943 PRINCETON, N.J., Feb. 14, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the National Institute of Allergy and Infectious Diseases (NIAID) has...

2014-02-05 08:28:42

Presentation to be Webcast Live on February 10, 2014 at 3 PM EST PRINCETON, N.J., Feb. 5, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD,...

2014-02-04 12:28:56

HONOLULU, Feb. 4, 2014 /PRNewswire/ -- The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded Hawaii Biotech, Inc. a grant to continue the development of anthrax anti-toxin drugs. The small molecule inhibitors under development block anthrax lethal toxin. The award has a first-year period of performance, through Q1 2014, valued at $1.1 million. The grant for the full five-year period equals $7.4 million. Under...